Elwyn Institute-Philadelphia is categorized under Rehabilitation Center, Outpatient Treatment in Philadelphia, PA and active since 2007.
Elwyn Institute-Philadelphia was established in 2007, and today employs 1 to 4, earning Unknown per year. This is a Rehabilitation Center, Outpatient Treatment business, which does work in the B2C market, and is classified as a Rehabilitation Center, Outpatient Treatment, under code number 6112100 by the NAICS.
If you are seeking more information, feel free to contact at the company’s single location by writing to 644 North 43rd St, Philadelphia, Pennsylvania PA 19104 or by phoning (215) 222-0122. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Elwyn Institute-Philadelphia |
Address: | 644 North 43rd St, Philadelphia, Pennsylvania 19104 |
Phone Number: | (215) 222-0122 |
Annual Revenue (USD): | Unknown |
Founded: | 2007 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Rehabilitation Center, Outpatient Treatment |
SIC Code: | 8093 |
NAICS Code: | 6112100 |
Share This Business: |
Elwyn Institute-Philadelphia was started in 2007 to provide professional Rehabilitation Center, Outpatient Treatment under the SIC code 8093 and NAICS code 6112100. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact for inquiries that concern Elwyn Institute-Philadelphia by calling the company number (215) 222-0122, as your correspondence is most welcome. Additionally, the physical location of the single location of Elwyn Institute-Philadelphia can be found at the coordinates 39.96376,-75.20931 as well as the street address 644 North 43rd St in Philadelphia, Pennsylvania 19104.
For its online presence, you may visit Elwyn Institute-Philadelphia’s website at and engage with its social media outlets through on Twitter and on Facebook.